Ardelyx Announces Departure of Chief Scientific Officer

News

  View printer-friendly version

<<  Back
Ardelyx Announces Departure of Chief Scientific Officer

FREMONT, Calif., Feb. 12, 2018 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that Jeremy Caldwell, Ph.D., chief scientific officer, will be leaving the company, effective February 16, 2018, to pursue a position as chief executive officer of an early stage biotech start-up company based in San  Diego.

Ardelyx logo (PRNewsFoto/Ardelyx)

"Jeremy has been a tremendous asset to Ardelyx, and I am incredibily grateful for his many contributions to the company and our programs over the years," said Mike Raab, president and chief executive officer of Ardelyx. "Jeremy has been instrumental in building our propriety platform, leading drug discovery efforts, like our RDX013 potassium secretagogue program, and supporting the development of tenapanor to where it is today. Our team will continue Jeremy's legacy as we work to bring important medicines to patients who need them. We will miss Jeremy's presence and the value that he has consistently contributed to our entire team. We wish him much success in this important new opportunity."

"My time with Ardelyx has been extremely rewarding, and I'm proud of the many accomplishments of this team," said Jeremy. "Since joining in 2014, we have brought forward several first-in-class programs, culminating in the first New Drug Application for tenapanor for IBS-C planned for submission in the second half of the year. I believe that tenapanor will play a critical role in treating both hyperphosphatemia and IBS-C in the future. I'm proud of what we've discovered with the RDX013 program, as it represents an entirely new approach to treating hyperkalemia. I look forward to watching these program progress, and want to thank everyone at Ardelyx for helping me reach this next stage in my career."

About Ardelyx, Inc.
Ardelyx is focused on enhancing the way people with cardiorenal diseases are treated by developing differentiated, minimally systemic medicines. Ardelyx's cardiorenal pipeline includes the Phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and RDX013, a potassium secretagogue program for the potential treatment of hyperkalemia. In addition to its cardiorenal pipeline, Ardelyx has completed Phase 3 development of tenapanor for the treatment of people with irritable bowel syndrome with constipation and anticipates submitting a New Drug Application to the U.S. Food and Drug Administration for this indication in the second half of 2018. To efficiently bring its treatments to market, Ardelyx is pursing strategic collaborations in the U.S. and beyond, with established agreements with Fosun Pharma in China and Kyowa Hakko Kirin in Japan. For more information, please visit http://www.ardelyx.com/ and connect with us on Twitter @Ardelyx.

Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including the potential for Ardelyx's product candidates in treating the diseases and conditions for which they are being developed; Ardelyx's expected timing for the filing of its NDA for tenapanor for the treatment of IBS-C, and Ardelyx's ability to establish collaborations in the future. Such forward-looking statements involve substantial risks and uncertainties that could cause the development of Ardelyx's product candidates or Ardelyx's future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in research and the clinical development process, including the regulatory approval process. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx's business in general, please refer to Ardelyx's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2017, and its future current and periodic reports to be filed with the Securities and Exchange Commission.

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/ardelyx-announces-departure-of-chief-scientific-officer-300596834.html

SOURCE Ardelyx

Monique Allaire, THRUST IR; 781-631-0759; monique@thrustir.com OR Alicia Davis, THRUST IR; 910-620-3302; alicia@thrustir.com